Allergic Disorder
5
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
5 treatments under study, led by Aslan004
Research Leaders
6 sponsors active, led by Sun Yat-sen University
Related Conditions
Often studied with 14 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (5)
No-worry Baby Project
Impact of Microbial Exposure of the Habitat at the Time of Birth on the Development of Allergic Diseases.
Importance and Association of Gut Microbiota and Biochemical Metabolites on Children Allergic Disorder
Study of ASLAN004 in Healthy Subjects
The Effects of Early Life PUFA and R-TFA on AD: A Systematic Review and Meta-analysis
Research Network
Common Treatments
- Aslan0041
- Pufa And Rtfa1
- Clinical Evaluation1
- Microbiota1
- No Intervention1
Active Sponsors
- Sun Yat-sen University2
- Chang Gung Memorial Hospital1
- ASLAN Pharmaceuticals1
- Huizhou No.1 Maternal and Child Care Service Cencer1
- IQVIA Pty Ltd1
Top Investigators
Sun Yat-sen University
CHU Brugmann
School of Public Health of Sun Yat-sen University
Related Conditions
- Gestational Hypertension1
- Asthma1
- Immune System Diseases1
- Neurodevelopmental Disorders1
- Obesity1